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Abstract
Background: Accurate assessments of ovarian reserve (OR) in egg donor candidates are crucial for maximal donor 
selection. This study assesses whether recently reported new methods of OR assessment by age-specific (as-), rather 
than non-as (nas-) hormones, follicle stimulating hormone (FSH) and anti-Müllerian hormone (AMH), and triple 
nucleotide (CGG) repeats on the FMR1 (fragile X) gene have the potential of improving egg donor selection.
Methods: Seventy-three consecutive egg donor candidates (candidates), amongst those 21 who reached egg retrieval 
(donors), were prospectively investigated for as-FSH, as-AMH and number of CGG repeats. Abnormal findings were 
assessed in candidates and donors and oocyte yields in the latter were statistically associated with abnormal FSH and 
AMH (>/< 95% CI of as-levels) and with normal/abnormal numbers of CGG repeats (normal range 26-32).
Results: Amongst candidates mean as-AMH was 3.8 +/- 2.8 ng/mL (37.0% normal, 3.0 +/- 0.7 ng/mL; 26.6% low, 1.5 +/
- 0.5 ng/mL; and 37.0% high, 5.8 +/- 2.2 ng/mL). AMH among donors was 4.2 +/- 1.7 ng/mL (33.3% normal, 14.3% low, 
and 52.4% high), yielding 17.8 +/- 7.2 oocytes, 42.9% in normal range (10-15), 9.5% in low (less than or equal to 9) and 
47.6.% in high range (16-32). Candidates in 41.9% and donors in 38.1% demonstrated normal CGG counts; the 
remained were mostly heterozygous abnormal.
Discussion: Prospective assessment of even carefully prescreened candidates and donors still demonstrates 
shortcomings on both ends of the OR spectrum. Utilization of ovarian reserve testing methods, like as-hormones and 
CGG repeats on the FMR1 gene have potential of improving candidate selections.
Background
Oocyte donor selection in the United States (U.S.) repre-
sents a highly complex process, catering to different,
guidelines and regulations [1]. A dominant medical need,
not affected by federal regulations, is to ascertain normal
ovarian function: Prematurely diminished ovarian
reserve (PDOR) in young donor candidates will nega-
tively affect oocytes yields [2], while excessive ovarian
response to stimulation can not only result in poor
oocytes quality [3] but lead to ovarian hyperstimulation
syndrome (OHSS), and endanger the physical wellbeing
of potential donors [4].
As for infertility patients, ovarian reserve (OR) in
oocyte donor candidates is traditionallyassessed via base-
line follicle stimulating hormone (FSH), especially at
younger ages reported to be a rather poor tool to detect
PDOR [2]. Anti-Müllerian hormone (AMH) appears to
better reflect OR [5], and is, therefore, increasingly uti-
lized to detect diminished ovarian reserve (DOR) [6,7]
and/or hyperstimulation risk in women with polycyctic
ovarian syndrome (PCOS) [8]. No studies on AMH utili-
zation in oocyte donor selection have, however, so far
been performed. This study does this.
Assessments of OR in infertile women as well as
oocytes donors, historically, practically exclusively,
involve non-age-specific (nas-) levels of FSH and/or
AMH. FSH, however, increases, and AMH decreases with
advancing female age, which makes such non-discrimina-
tory use of normal cut off values appear illogical. We,
therefore, proposed utilization of age-specific (as-) cut off
values for FSH [2] and AMH [5], both found to be supe-
rior in determining OR: AMH at all ages [2,5] and FSH
under age 38 years discriminate better between higher
and poorer oocytes yields with in vitro fertilization (IVF)
than previously utilized nas-values [2,6,9]. The utilization
of as-AMH can also be helpful in determining ovarian
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hyperstimulation risk [5]. How as-OR testing impacts
oocyte donor selection has, however, so far, not been
investigated. This study investigates this issue.
Numbers of CGG triple nucleotide repeats on the
FMR1 gene statistically relate to risk towards PDOR [10-
12], with 26 to 34 repeats representing a normal range of
counts in regards to the genes effects on ovarian function
[13,14] (to be differentiated from normal and abnormal
ranges of repeats in regards to neuro/psychiatric risks
associated with the gene). Deviations from this normal
range denote specific ovarian aging patterns, defined by
varying rates of decline in OR [14]. In an infertile popula-
tion, CGG counts also correlate to OR, as reflected by
oocytes yields in IVF [11]. A specific heterozygous (nor-
mal/low) CGG repeat pattern appears to predispose
towards a normal weight polycystic ovary phenotype
[12].
The evaluation of triple CGG counts on the FMR1gene,
thus, also offers potentially important clinical informa-
tion about OR in young women. What such evaluations
could contribute to egg donor screening has, however,
not previously been investigated, and represents, there-
fore, together with as-FSH and as-AMH, the third new
tool evaluated in this study for its potential to improve
oocytes donor selection.
Methods
Patient population
Since July, 2007, the center evaluated 164 applicants as
potential egg donors who, based on a detailed question-
naire, qualified for further investigation. Amongst those,
73 (ages 19 to 33 years, mean 24.2 +/- 3.6) reached, after
two interviews, a first laboratory screening stage, thus
becoming candidates for egg donation. At this stage they
underwent vaginal ultrasonography, random AMH and
genetic testing, including determination of number of tri-
ple nucleotide (CGG) repeats on the FMR1(fragile X)
gene, for which patients signed an FMR1-specific
informed consent.
Laboratory assays
S i n c e  F S H ,  i n  c o n t r as t  t o  AM H ,  r eq u i r e s  t i m ed  b l ood
draws [5], it was only evaluated in candidates who
became donors by reaching ovarian stimulation.
FSH, estradiol and AMH were evaluated as previously
described [5]. In short, FSH and estradiol were obtained
on cycle days 2/3 and assessed utilizing a standard
enzyme-linked immunoabsorbent assay (ELISA, AIA-
60011, Tosho, Tokyo, Japan). Only results in assay range
were considered for statistical evaluation. AMH was also
evaluated by ELISA.[DSL-10-14400 active Müllerian
Inhibiting Substance/Anti-Müllerian Hormone (MIS/
AMH) enzyme-linked immunoabsorbent (ELISA), Diag-
nostic System Laboratories, Inc., Webster, TX 77598-
4217, USA], an enzymatically amplified two-site immu-
noassay, which does not cross-react with other members
of the TGF-β super family, including TGF-β1, BMP4 and
ACT [15]. Theoretical sensitivity, or minimum detection
limit, calculated by interpolation of mean plus two stan-
dard deviations of eight replicates of the 0 ng/mL MIS/
AMH Standard, was 0.0006 ng/mL. Intra-assay coeffi-
cient of variation for an overall average AMH concentra-
tion was reported as ≤ 10 percent [15] and in our hands <
15%. Results are presented in ng/mL, with a conversion
factor of 7.14 to pmol/L [16].
Normal as-AMH and FSH levels have previously been
published, based on 95%confidence intervals (CI) at all
ages [2,5]. Figure 1 summarizes as-FSH and AMH levels
as recently reported elsewhere [7].
Numbers of triple CGG repeats on the FMR1 gene were
evaluated, utilizing commercial assays, as also previously
described [10,11]. In short, FMR1 assays were performed
testing DNA by Southern blot and polymerase chain
reaction (PCR) to determine size and methylation status
of CGG repeats. Southern blot analysis was performed
using probe St.B12.3 on EcoR1 and Eagle digested DNA.
PCR products were generated using fluorescent labeled
primer, and were sized by capillary electrophoresis.
We previously defined and reconfirmed a normal range
of CGG repeats as 26 to 34, with median at 30 repeats
[13,14]. Women who's both allele counts fell into this
range were considered normal; Those who demonstrated
one allele in range and one outside, were considered
heterozygous-abnormal, with normal/low (norm/low)
and normal/high (norm/high) being separately evaluated.
Those with both alleles in abnormal range were consid-
ered homozygous- abnormal.
Statistics
All data are expressed as mean +/- standard deviation
(SD); a p-value < 0.05 was considered statistically signifi-
cant. Differences between normally distributed variables
were tested with analysis of variance or covariance. Dif-
ferences between groups of variables not conforming to
normality were tested for with the Mann-Whitney test.
All analyses were carried out with SPSS software for Win-
dows version 17.0, 2005 (SPSS Inc. Chicago, IL.)
Institutional Review Board
Our center's Institutional Review Board allows review of
medical records for research purposes under expedited
review, as long as patients sign an appropriate informed
consent. This consent warrants that the chart review will
maintain their anonymity and protect the patients' iden-
tity. These conditions were met for this study. In addition,
all patients also signed a FMR1-specific consent.Gleicher et al. Reproductive Biology and Endocrinology 2010, 8:76
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Figure 1 as-FSH and AMH levels. as-FSH and as-AMH levels in candidates are shown against normal as-ranges previously established [5]. As the fig-
ure demonstrates, a considerable number of candidates demonstrate values outside of normal as-range for both, AMH and FSH.
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Results and Discussion
Amongst a total of 164 consecutive egg donor applicants,
73 reached initial AMH evaluations and FMR1 gene anal-
yses and, thus, became donor candidates. As described in
Table 1, their mean age was 24.2 +/- 3.6 years (range 19 -
34) and mean AMH was 3.7 +/- 2.8 ng/mL (range 0.6 to
13.0).
Amongst those, 27 (37.0%) demonstrated AMH values
within a normal as-range (mean, 3.0 +/- 0.7 ng/mL); 19
(26.0%) had low as-AMH, suspicious of DOR, (mean 1.5
+/- 0.5 ng/mL); and another 27 (37.0%) demonstrated
abnormally elevated as-AMH levels, suspicious of PCOS
(mean 5.8 +/- 2.2 ng/mL) and, therefore, potentially
reflected hyperstimulation risk (Figure 1). Only 17 candi-
dates had baseline FSH levels, and those ranged from 3.1
to 9.8 mIU/mL (Figure 1).
FMR1 analyses amongst candidates demonstrated nor-
mal distribution of CGG repeats on both alleles in 30
(41.1%), with 39 (53.4%) being heterozygous abnormal,
amongst those 15 (20.6%) being het-norm/low and 24
(32.9%) being het-norm/high. Four candidates (5.5%)
were homozygous, two (2.7%) each hom-low/high and
hom-high/high but none were hom-low/low. (Table 1).
Overall mean distribution of CGG repeats on both alleles
did not vary significantly between candidates and donors
(Table 1, Figure 2).
Analysis of oocytes yield in 21 candidates who by time
of study analysis became donors and, therefore, reached
oocytes retrievals allowed limited correlations to FSH,
AMH and FMR1 status. Mean age was 24.1 +/- 3.5 years
(range 19 - 34) and they yielded 17.8 +/- 7.2 oocytes
(range 6 - 32). AMH levels were 4.2 +/- 1.7 ng/mL (range,
1.6 - 7.9) and FSH levels 5.9 +/- 2.0 mIU/mL (range 3.1 -
9.8) (Table 1).
A total of 14/21 (66.7%) of donors demonstrated abnor-
mal as-AMH; amongst those 3/21 (14.3%) abnormally
low and 11/21 (52.4%) abnormally high values. Values of
Figure 2 Distribution of CGG counts on FMR1 gene in candidates. 
The differences in distribution were not significant.
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Table 1: Characteristics of donor candidates and donors
Candidates Donors
(n = 73) (n = 21)
Age (years; mean ± SD) 24.2 ± 3.6 24.1 ± 3.5
Total oocyte yield n/a 17.8 ± 7.2
AMH (ng/mL; mean ± SD) 3.7 ± 2.8 4.2 ± 1.7
as-AMH normal (% of total1) 3.0 ± 0.7 (37.0) 3.2 ± 0.6 (33.3)
Oocyte yield2 n/a 20.7 ±9.1
low 1.5 ± 0.5 (26.0) 1.8 ± 0.2 (14.3)
Oocyte yield2 n/a 15.7 ± 3.8
high 5.8 ± 2.2 (37.0) 5.4 ± 1.4 (52.4)
Oocyte yield2 n/a 16.5 ± 6.4
FSH (mIU/mL: mean ± SD) n/a 5.9 ± 2.0
as-FSH normal (% of total1) n/a 5.0 ± 1.3 (76.5)
high n/a 8.5 ± 1.3 (23.5)
FMR1: number of CGG repeats
Allele-1 29.1 ± 3.3 29.0 ± 3.2
Allele-2 32.4 ± 2.2 32.2 ± 2.0
Normal3 n (%) 30 (41.1) 9 (42.9)
AMH (ng/mL; mean ± SD) 3.3 ± 1.6 4.0 ± 1.5
Heterozygous 3 n (%) 39 (53.4) 12 (57.1)
AMH (ng/mL; mean ± SD) 3.9 ± 2.7 4.0 ± 1.6
Het-norm/low n (%) 15 (20.6) 4 (19.0)
AMH (ng/mL; mean ± SD) 3.3 ± 2.3 3.9 ± 1.2
Het-norm/high n (%) 24 (32.9%) 8 (38.1)
AMH (ng/mL; mean ± SD) 4.4 ± 3.0 4.0 ± 1.9
Homozygous3 n (%) 4 (5.5) 0
Hom-high/high 2 (2.7) -
Hom-low/high 2 (2.7) -
Hom-low/low 0 0
The Table summarizes patient characteristics in 73 consecutive egg 
donor candidates, who after an elimination process (for details see 
Materials and Methods section) reached a first laboratory testing 
stage and, from amongst them 21 who reached egg retrieval (one 
donor did not have FMR1 testing) (donors).
Candidates and donors did not differ statistically in any parameter.
1 Reflects percentage of patients in total group.
2 AMH does not distinguish between donors with normal or 
abnormal yields (p = 0.83).
3 Normal is defined by both alleles demonstrating between 26-34 
CGG repeats; in heterozygous women one allele demonstrates a 
count outside of this normal range, with het-norm/low defining an 
abnormally low and het-norm/high and abnormally high count.Gleicher et al. Reproductive Biology and Endocrinology 2010, 8:76
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as-FSH were abnormally elevated in 4/17 donors (23.5%)
and normal in 13/17 (76.5%).
CGG counts were normal in 9/21 (42.9%) and heterozy-
gous-abnormal in 11/21 (57.1%) of donors, 4/21 (19.0%)
with heterozygous genotype of norm/low and 8/21
(38.1%) with norm/high (Table 1).
Investigating abnormalities in laboratory findings as
predictors of oocytes yields, 2/21 (9.5%) donors produced
abnormally low (≤ 9) oocytes numbers (7 and 6, respec-
tively), 10/21 (47.6%) produced abnormally high oocytes
yields (range 16-32) and only 9/21 (42.9%) showed egg
numbers considered to be in a normal range of 10-15
(Table 2). In two donors with abnormally low oocytes
production AMH was normal and high, respectively; FSH
was available in only one and was normal; and both dem-
onstrated heterozygous abnormal CGG counts, one nor-
mal/high and the other normal/low.
Subgroups were too small to reach statistically valid
conclusions, cross-tabulating oocytes yields and as-AMH
levels. Donors with abnormally high oocytes yields dem-
onstrated in 40.0% normal as-AMH, in 50.0% abnormally
high and in 10.0% abnormally low values. Donors with
normal oocytes numbers demonstrated normal as- AMH
in 22.2%, abnormally high levels in 55.6% and abnormally
low as-AMH in 22.2%. AMH statistically did not distin-
guish between normal and abnormally high oocytes
yields (p= 0.83).
Six out of seven donors (85.7%) with high oocytes yields
demonstrated normal as-FSH, while only 4/7 (57.1%)
with normal egg numbers showed normal FSH values and
3/7 (42.9%) elevated as-FSH. These differences were,
however not statistically different.
Investigating associations between oocytes yields and
CGG counts, all nine women with counts on both alleles
in normal range (26-34) demonstrated either normal (6/
9, 66.6%) or high (3/9, 33.3%) egg numbers. None had
abnormally low oocytes yields. Otherwise, small patient
numbers did not allow for further statistically robust con-
clusions.
In the U.S., the selection of oocytes donors has become
increasingly complex since the Food and Drug Adminis-
tration (FDA) has assumed regulatory authority [1]. The
FDA's interests primarily, however, extend to infectious
transmission risks. Other aspects of candidate selection
are left to patients and physicians. Oocytes (and embryo)
yields are, amongst those, of great importance. Correct
assessments of OR in oocyte donation candidates repre-
sent, therefore, a very essential part of the egg donation
process.
A number of perceptive papers recently well summa-
rized progress in assessing OR [17-20]. Most concen-
trated on the utilization of AMH, with consensus
evolving that AMH may, overall, be a better reflection of
OR than baseline FSH [5,8,9,21]. This should not sur-
prise: While AMH and FSH correlate [22], both, in prin-
ciple, reflect different stages of follicular maturation,
AMH small, preantral and FSH more mature, preovula-
tory follicles [17]. As OR is defined to reflect remaining
follicles in ovaries, the larger preantral pool should,
indeed, better reflect OR than preovulatory follicles, pri-
marily represented by FSH.
Though predictive values of FSH [2,23] and AMH [5]
change as females age, and even though as-evaluations
offer distinct advantages over nas-testing [2,5], OR evalu-
Table 2: Percentage distribution of oocyte yields in donors
Oocyte yield Normal Low High
(n oocytes) 10-15 (≥ 9) (16-32)
n donors (%) 9 (42.9) 2 (9.5) 10 (47.6)
as-AMH normal (%) 28.6 14.3 57.1
low (%) 66.7 0 33.3
high (%) 45.5 9.1 45.5
as-FSH normal (%)1 57.1 100.0 85.7
high (%) 42.9 0 14.3
FMRI numbers of CGG repeats
Normal (%) 66.6 0 33.3
Heterozygous2 ---
Homozygous2 ---
1 FSH values did not statistically discriminate between normal and abnormal oocytes yields.
2 Numbers too small for statistical evaluation;Gleicher et al. Reproductive Biology and Endocrinology 2010, 8:76
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ations still, almost uniformly, utilize nas-normal ranges,
independent age. The former, however, also can be
expected to improve OR assessments in oocyte donation
candidates. This study supports this assumption by dem-
onstrating that a surprisingly large number of them fall
outside normal as-OR testing parameters and are, there-
fore, at risk for either too low or to high oocytes yields. As
Table 1 demonstrates, only 37.0 percent of candidates and
33.3 percent of donors demonstrated normal as-AMH,
only 76.5 percent of donors normal FSH and only 41.1
percent of candidates and 42.9 percent of donors normal
CGG counts.
as- FSH, as-AMH and CGG counts are new tools in
defining OR. They never before were applied to selection
of oocytes donation candidates. Since oocytes donation is
a voluntary and costly process, risks to donors and costs
to recipients have to be minimized. Improvements in OR
assessments facilitate both: better risk prediction of
excessive oocytes yields should eliminate most OHSS
risks. Carlesen and associates reported that abnormally
high as-AMH denote such risk [8]. At the other extreme,
avoidance of disappointing oocytes yields, reduces
unnecessary costs.
The frequency of as-AMH abnormalities was surpris-
ing. So far, only few studies reported cut-off values sug-
gestive of DOR (and/or poor oocytes/embryo quality)
[5,16] and of OHSS risk [8,9]. This study utilized as-AMH
levels, based on 95% CIs of patients of all ages at our
cente. Women with AMH below the lower cut off were
considered at risk for DOR; those above the 95% CI for
their age were considered at OHSS risk. These levels have
previously been demonstrated to discriminate abnor-
mally low and abnormally high oocytes yields [5].
Remarkably, only approximately one third of donation
candidates (37.0%) demonstrated normal as-AMH;
approximately a quarter (26.0%) exhibited abnormally
low AMH and were, therefore, at risk for low oocytes
production; and another remarkable 37.0 percent pro-
duced abnormally high levels, placing them at risk for
OHSS.
Relatively small donor numbers prevent this pilot study
from outright statistical conclusions on specific benefits
from here utilized, new OR assessment techniques in
oocytes donation cycles. Statistical trends, however, uni-
formly, and without exception, support a positive effect
on donor selection: As Table 1 demonstrates, AMH levels
increased from candidates to donors from 3.7 +/- 2.8 to
4.2 +/- 1.7 ng/mL. Moreover, AMH levels increased in
candidates with normal as-AMH (3.0 +/-0.7 to 3.2 +/- 0.6
ng/mL) and low as-AMH (1.5 +/- 0.5 to 1.8 +/- 0.2 ng/
mL) but decreased in candidates with high as-AMH who
became donors (5.8 +/- 2.2 to 5.4 +/- 1.4 ng.mL).
These opposing trends, are, of course, exactly what one
would expect as a consequence of better donor selection,
with OR improving (improving AMH levels) from candi-
date status to donor status in women with lower OR and
declining (declining AMH) from candidate to donor sta-
tus in those with excessively high OR.
Though, especially amongst donors, subgroups became
too small to reach statistically robust conclusions, corre-
lations with oocytes yields, nevertheless, were remarkable
(Table 2): 9.5 percent demonstrated low oocytes yields (≤
9), approximately half, high oocytes numbers (16-32) and
approximately 40% normal oocytes yield (10-15). Oocytes
yields with normal (20.7 +/- 9.1 oocytes) and high as-
AMH (16.5 +/- 6.4 oocytes) were higher than with low as-
AMH (15.7 +/- 3.8 oocytes), though differences failed to
reach significance. The data, however, correlate well with
earlier reports that as-AMH discriminates between lower
and higher oocytes yields [5,7].
The study, therefore, suggests that as-AMH may,
indeed, improve egg donor selection. The large number
of candidates, by here utilized criteria defined at risk for
OHSS,would, however, suggest that as- 95% CIs may rep-
resent too low a cut off. Nelson et al defined OHSS risk
even lower at nas-AMH above 15 pmol/L (2.1 ng/ml) [9].
A better definition of OHSS risk, therefore, awaits addi-
tional studies, preferably utilizing as-AMH values.
Candidates also demonstrated a significant prevalence
of abnormal CGG counts on their FMR1  genes. This
should, however, not surprise since Fu et al reported in
normal populations a large distribution peak between 29
and 30 repeats but significant additional distribution at
lower and higher numbes [24]. We found this peak
intriguing and hypothesized that it may represent a nor-
mal distribution range in regards to potential OR-related
function of the gene [13,14].
In this study a little less than half of all candidates
(41.1%) and donors (42.9%) showed normal distribution,
53.4 percent of candidates and 57.1 percent of donors
demonstrated heterozygous abnormalities. Only candi-
dates (5.5%), but no donors, demonstrated homozygous
abnormalities. Donors reaching retrieval, thus, demon-
strated a very similar distribution pattern to candidates
(Table 1).
Like general populations, egg donors can, therefore be
expected to demonstrate significant CGG count abnor-
malities. Since such abnormalities may denote different
time patterns in decline of OR, such information may be
helpful in egg donor selection, especially if donor candi-
dates are in their later 20ies, when FMR1 CGG count pat-
terns can already significantly affect OR [14].
H e r e  r e p o r t e d  o o c y t e s  y i e l d  d a t a  h a v e  t o  b e  v i e w e d
with caution since, like in any retroactive analysis, they
already reflect integration of knowledge from earlier
screening stages. Some here reported donors, therefore,
may have yielded fewer oocytes had they not been recog-
nized as at risk towards DOR, and received appropriatelyGleicher et al. Reproductive Biology and Endocrinology 2010, 8:76
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modified stimulation. Integration of earlier OR screening
data may, therefore, have possibly blunted otherwise
more prominent differences. Similarly, IVF programs
integrate clinical suspicion for PCOS into cycle manage-
ment, whether based on the sonographic appearance of
ovaries or high AMH levels.
Conclusions
In summary, here presented data suggest that as-FSH, as-
AMH and FMR1  testing may be helpful in further
improving egg donor selection. To what degree, will,
however, remain to be determined. Such a conclusion is
also supported by general advantages of as-testing over
nas-OR testing and very predictive patterns of ovarian
aging associated with CGG repeats on the FMR1 gene.
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